The impact of vitreomacular traction on vitreous vascular endothelial growth factor and placental growth factor levels in neovascular age-related macular degeneration patients
- PMID: 39528811
- PMCID: PMC11750961
- DOI: 10.1038/s41433-024-03456-9
The impact of vitreomacular traction on vitreous vascular endothelial growth factor and placental growth factor levels in neovascular age-related macular degeneration patients
Abstract
Purpose: To investigate the effect of vitreomacular traction (VMT) on vitreous vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) levels in patients with active neovascular age-related macular degeneration (nAMD).
Design: A prospective, interventional, case-control study.
Methods: The study included a total of 70 patients from whom vitreous samples were obtained. The patients were categorized into four group: 10 patients with active nAMD accompanying VMT, 17 patients with VMT, 24 patients with active nAMD and 19 healthy patients without any diagnosis other than cataract. VEGF and PlGF levels were measured.
Results: The mean vitreous VEGF level was 34.7 ± 4.98 pg/ml in the nAMD and VMT group, 32.36 ± 4.55 pg/ml in the VMT group, 34.02 ± 3.79 pg/ml in the nAMD group, and 32.33 ± 2.4 pg/ml in the healthy control group. The mean vitreous PlGF level was 58.92 ± 20.83 pg/ml in the nAMD and VMT group, 46.29 ± 3.45 pg/ml in the VMT group, 54.64 ± 16.88 pg/ml in the nAMD group, and 53.66 ± 19.35 pg/ml in the healthy control group. No significant differences were observed in terms of vitreous VEGF and PlGF concentrations among the groups (p > 0.05 and p > 0.05, respectively). Aqueous humour VEGF and PlGF levels were significantly higher than vitreous levels in nAMD patients (p = 0.005 and p = 0.005, respectively).
Conclusion: The present study found no increases in vitreous VEGF and PlGF levels in both VMT + nAMD and VMT cases. Furthermore, patients with nAMD had significantly higher levels of PlGF and VEGF in aqueous humour compared to vitreous levels.
© 2024. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Similar articles
-
Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: A systematic review and meta-analysis.Photodiagnosis Photodyn Ther. 2023 Jun;42:103555. doi: 10.1016/j.pdpdt.2023.103555. Epub 2023 Apr 23. Photodiagnosis Photodyn Ther. 2023. PMID: 37088331
-
Recovery of plasma vascular endothelial growth factor concentrations during aflibercept loading phase and after the transition to bimonthly treatment for neovascular age-related macular degeneration.Br J Ophthalmol. 2015 Dec;99(12):1610-3. doi: 10.1136/bjophthalmol-2015-306781. Epub 2015 May 12. Br J Ophthalmol. 2015. PMID: 25966740 Clinical Trial.
-
Real-world outcomes of a loading phase with intravitreal faricimab in refractory Neovascular Age-Related Macular Degeneration (nAMD) patients.BMC Ophthalmol. 2025 Jul 1;25(1):347. doi: 10.1186/s12886-025-04212-7. BMC Ophthalmol. 2025. PMID: 40598116 Free PMC article.
-
Association of plasma metabolites with treatment response after intravitreal anti-vascular endothelial growth factor injections in treatment-naïve neovascular age-related macular degeneration.BMJ Open Ophthalmol. 2025 Mar 15;10(1):e002149. doi: 10.1136/bmjophth-2025-002149. BMJ Open Ophthalmol. 2025. PMID: 40090700 Free PMC article.
-
Anti-vascular endothelial growth factor for neovascular glaucoma.Cochrane Database Syst Rev. 2023 Apr 3;4(4):CD007920. doi: 10.1002/14651858.CD007920.pub4. Cochrane Database Syst Rev. 2023. PMID: 37010901 Free PMC article.
Cited by
-
Updates on novel and traditional OCT and OCTA biomarkers in nAMD.Eye (Lond). 2025 Jun;39(9):1662-1672. doi: 10.1038/s41433-025-03801-6. Epub 2025 Apr 19. Eye (Lond). 2025. PMID: 40253504 Review.
References
-
- Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, et al. The International Vitreomacular Traction Study Group classification of vitreomacular adhesion, traction, and macular hole. Ophthalmology. 2013;120:2611–9. - PubMed
-
- Lee EK, Lee SY, Lee JY, Heo JW, Yu HG, Chung H. Anatomical configurations of vitreomacular traction syndrome: influence on clinical course and surgical outcomes. Graefes Arch Clin Exp Ophthalmol. 2019;257:1631–9. - PubMed
-
- Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004;137:486–95. - PubMed
-
- Wong WL, Su X, Li X, Cheung CM, Klein R, Cheng CY, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–116. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources